



Extracta DBS

Cat No: 95171-010
95171-500

Size: 10 mL
500 mL

Store at 2°C to 8°C

Description

Extracta DBS is a ready-to-use DNA extraction reagent for rapid and efficient recovery of PCR-ready DNA from dried blood spots (DBS) on Guthrie cards or Whatman 903 filter paper. This patented single-solution process produces DNA that is suitable for a variety of downstream applications including real-time qPCR or template generation for Next Generation Sequencing (NGS) or Sanger sequencing (1-3). DNA eluates are substantially free of PCR inhibitors and compatible with a variety of end-point PCR or real-time qPCR reagents. Application of Extracta DBS with PerfeCta® qPCR ToughMix® or PerfeCta® MultiPlex qPCR ToughMix enables accurate and reproducible quantification of DNA sequences in blood using TaqMan® hydrolysis probe real-time qPCR.

Components

Extracta DBS 1X concentrated, ready-to-use, proprietary DNA extraction reagent

Storage and Stability

Extracta DBS is stable for up to 2 years at 2°C to 8°C.

For lot specific expiry date, refer to package label, Certificate of Analysis or Product Specification Form

Recommended Protocol for DNA Isolation from Dried Blood Spots (DBS)

1. Place a single 3.2 mm punch from DBS specimen in each PCR tube or well of a PCR plate.
2. Add 100 µL of Extracta DBS reagent and rinse the DBS punch by gentle vortexing or pipetting up and down.
3. Cap the tubes (or seal the plate) and centrifuge at ~3,500 rpm for 5 minutes.
4. Using a pipettor, remove as much liquid and debris as possible and discard the rinse into 10% bleach or in accordance with your institution's safety policies for processing dried blood spot specimens.
5. Add 50 µL of fresh Extracta DBS reagent to each rinsed DBS specimen.
6. Cap the tubes (or seal the plate) and then briefly centrifuge (10-30s) at ~3,500 rpm to ensure that the punch is completely submerged in the reagent.
7. Place the tubes or plate in a thermal cycler with a heated lid and incubate at 95°C for 20 minutes, then hold at 4-8°C.
8. Remove the tubes or plate from the thermal cycler and use up to 5 µL of extracted DNA as template in each 20-25-µL PCR.

Note: it is normal for the extracted DNA solution to have a pink color.

Extracted DNA should be used immediately in down-stream amplification procedures. It may be refrigerated at 2-8°C for short term storage before PCR amplification. The effect of prolonged storage on specific applications may vary.

Reagents and Equipment Required but not Provided

- Microcentrifuge tubes (0.5 mL or 1.5 mL), PCR tubes (0.2 mL) or multiwell plates
- P100 / P200 pipettor or multichannel pipettor
- PCR reagents
- Thermal cycler

Related Products

PerfeCta qPCR ToughMix, 250R Cat. No. 95112-250,
PerfeCta qPCR ToughMix, 5000R, Cat. No. 95112-05K,
PerfeCta qPCR ToughMix, 1250R, Cat. No. 95112-012

PerfeCta qPCR ToughMix ROX, 250R, Cat. No. 95113-250,
PerfeCta qPCR ToughMix ROX, 5000R, Cat. No.95113-05K,
PerfeCta qPCR ToughMix ROX, 1250R, Cat. No. 95113-012

PerfeCta qPCR ToughMix L-ROX, 250R, Cat. No.95114-250,
PerfeCta qPCR ToughMix L-ROX, 5000R, Cat. No.95114-05K,
PerfeCta qPCR ToughMix L-ROX, 1250R, Cat. No.95114-012

PerfeCta Multiplex qPCR ToughMix, 250R, Cat. No.95147-250,
PerfeCta Multiplex qPCR ToughMix, 1000R, Cat. No.95147-01K,
PerfeCta Multiplex qPCR ToughMix, 5000R, Cat. No.95147-05K

PerfeCta Multiplex qPCR ToughMix, ROX 250R, Cat. No. 95148-250,
PerfeCta Multiplex qPCR ToughMix, ROX 1000R, Cat. No. 95148-01K,
PerfeCta Multiplex qPCR ToughMix, ROX 5000R, Cat. No. 95148-05K

PerfeCta Multiplex qPCR ToughMix, L-ROX 250R, Cat. No. 95149-250,
PerfeCta Multiplex qPCR ToughMix, L-ROX 1000R, Cat. No.95149-01K,
PerfeCta Multiplex qPCR ToughMix, L-ROX 5000R, Cat. No.95149-05K

Limited Label Licenses

Use of this product signifies the agreement of any purchaser or user of the product to the following terms:

1. The product may be used solely in accordance with the protocols provided with the product and this manual and for use with components contained in the kit only. QIAGEN Beverly, Inc. grants no license under any of its intellectual property to use or incorporate the enclosed components of this kit with any components not included within this kit except as described in the protocols provided with the product, this manual, and additional protocols available at www.quantabio.com. Some of these additional protocols have been provided by Quantabio product users. These protocols have not been thoroughly tested or optimized by QIAGEN Beverly, Inc.. QIAGEN Beverly, Inc. neither guarantees them nor warrants that they do not infringe the rights of third-parties.
2. Other than expressly stated licenses, QIAGEN Beverly, Inc. makes no warranty that this kit and/or its use(s) do not infringe the rights of third-parties.
3. This kit and its components are licensed for one-time use and may not be reused, refurbished, or resold.
4. QIAGEN Beverly, Inc. specifically disclaims any other licenses, expressed or implied other than those expressly stated.
5. The purchaser and user of the kit agree not to take or permit anyone else to take any steps that could lead to or facilitate any acts prohibited above. QIAGEN Beverly, Inc. may enforce the prohibitions of this Limited License Agreement in any Court, and shall recover all its investigative and Court costs, including attorney fees, in any action to enforce this Limited License Agreement or any of its intellectual property rights relating to the kit and/or its components.

©2018 QIAGEN Beverly Inc. 100 Cummings Center Suite 407J Beverly, MA 01915

Quantabio brand products are manufactured by QIAGEN, Beverly Inc.

Intended for molecular biology applications. This product is not intended for the diagnosis, prevention or treatment of a disease.

This product is licensed under US Patent 9,206,468 and foreign equivalents for non-commercial research purposes only.

References

- Baker et al. 2016. Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study. *Genet Med.* 18(3):231-238.
- Baker et al. 2010. Implementing Routine Testing for Severe Combined Immunodeficiency within Wisconsin's Newborn Screening Program. *Public Health Rep.* 125 Suppl 2, 88-95.
- Verbsky et al. 2012. Newborn Screening for Severe Combined Immunodeficiency; The Wisconsin Experience (2008-2011). *J. Clin. Immunol.* 32, 82-88.

Trouble Shooting Guide

Problem	Possible Cause	Solution
No PCR product or non-specific product (or signal) from positive control samples using purified genomic DNA	PCR primers, reagents or cycling conditions were not optimal	Refer to the appropriate PCR reagent product manual to optimize PCR conditions
No PCR product or non-specific product (or signal) from extracts	Inadequate extract heating	Ensure that DBS punch extracts are incubated at $\geq 95^{\circ}\text{C}$. Program thermal cycler for 96°C .
	Extraction time was too short	Incubate sample in extraction reagent for up to 30 minutes at 95°C .
	Too much extract or template in PCR	Use less than 1/10 volume of extract in the PCR reaction. Extracts can be diluted 5-, 10-, 20-fold or more in TE buffer (10 mM Tris-HCl pH 8.0, 0.1 mM EDTA) prior to PCR.

PerfeCta, and ToughMix are trademarks of QIAGEN Beverly, Inc... TaqMan is a registered trademark of Roche Molecular Systems, Inc.